Related Experiment Videos

In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae

S Ioannidou1, P T Tassios, L Zachariadou

  • 1Department of Hygiene and Epidemiology, Medical School, Athens University, 115 27 Athens (Goudi), Greece.

Insights

This study assessed macrolide and telithromycin resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Most resistant strains showed the M phenotype, driven by the mefA/E gene, with telithromycin proving most effective.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Streptococcus pneumoniae and Streptococcus pyogenes are significant human pathogens.
  • Macrolide resistance in these bacteria is a growing public health concern.
  • Understanding resistance mechanisms is crucial for effective treatment strategies.

Purpose of the Study:

  • To determine the susceptibility of Streptococcus pneumoniae and Streptococcus pyogenes to macrolides and telithromycin.
  • To investigate the mechanisms of macrolide resistance in these bacterial species.
  • To compare the in vitro activity of telithromycin against erythromycin and clarithromycin.

Main Methods:

  • Susceptibility testing using Etest for macrolides and telithromycin.
  • Phenotypic determination of macrolide resistance mechanisms via double disk induction test.
  • Genetic determination of resistance mechanisms using PCR to detect the mefA/E gene.

Main Results:

  • High rates of erythromycin resistance were observed in both S. pneumoniae (42.8%) and S. pyogenes (30.8%).
  • A majority of erythromycin-resistant isolates (57.5% of S. pneumoniae, 59.5% of S. pyogenes) exhibited the M phenotype and carried the mefA/E gene.
  • Telithromycin demonstrated superior activity against both species compared to erythromycin and clarithromycin, indicated by lower MIC50 and MIC90 values.

Conclusions:

  • The mefA/E gene and M phenotype are prevalent mechanisms of macrolide resistance in Greek isolates of S. pneumoniae and S. pyogenes.
  • Telithromycin is a promising therapeutic option due to its potent activity against these resistant strains.
  • Continued surveillance of antimicrobial resistance patterns is essential for guiding clinical practice.

Related Concept Videos